Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 December, 2014 12:51 IST
Dr Reddys gets USFDA nod for Sildenafil tablets
Source: IRIS | 19 Nov, 2012, 09.43AM
Comments  |  Post Comment

Dr Reddys Laboratories, an integrated global pharmaceutical company,  announced that it has launched Sildenafil tablets (20 mg), a bioequivalent generic version of Revatio (Sildenafil) tablets in the US market.

It has received approval by the United States Food & Drugs Administration (USFDA) for ANDA Sildenafil tablets.

The Revatio brand had US sales of approximately USD 338.67 million for the most recent 12 months ending September 2012 according to IMS health.

Shares of the company gained Rs 16, or 0.91%, to trade at Rs 1,773.35. The total volume of shares traded was 755 at the BSE (9.32 a.m., Monday).



Dr Reddy`S Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Induslnd Bank expands presence across Rajasthan - 26-Dec-2014 17:02
ICICIdirect maintains `Buy` on Mastek - 26-Dec-2014 16:57
HDFC Securities maintains `Neutral` on Union Bank of India - 26-Dec-2014 16:49
Induslnd Bank expands presence across Delhi NCR - 26-Dec-2014 16:33
Lupin gets FDA approval for Generic Epivir tablets - 26-Dec-2014 16:19
Dr Reddys clarifies on news report - 26-Dec-2014 15:51
HDFC Securities maintains `Buy` on Bank of Baroda - 26-Dec-2014 14:33
NMDC names Satpathy as director - 26-Dec-2014 13:45
Reliance Capital to issue 7 mn shares to Sumitomo Mitsui - 26-Dec-2014 13:28
Zensar announces multimillion dollar deals in infrastructure biz - 26-Dec-2014 12:42
Market wide rollover at 83.05% vs. 85.33%: ICICIdirect - 26-Dec-2014 11:47
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer